- Pfizer’s Talzenna snags broader prostate cancer nod than AstraZeneca and Merck’s rival PARP med FiercePharma
- Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval Yahoo Finance
- FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC OncLive
- FDA Approves Talazoparib, Enzalutamide Combination for Metastatic Castration-Resistant Prostate Cancer Pharmacy Times
- FDA Approves Talzenna-Xtandi Combo for Subset of Patients With Prostate Cancer Curetoday.com
- View Full Coverage on Google News
Read More: Pfizer’s Talzenna snags broader prostate cancer nod than AstraZeneca and Merck’s